CA2940918C - Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-.alpha.]pyrazine derivatives and 5,6,7,8-tetrahydro-4h-pyrazolo[1,5-.alpha.][1,4]diazepine derivatives as ros1 inhibitors - Google Patents
Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-.alpha.]pyrazine derivatives and 5,6,7,8-tetrahydro-4h-pyrazolo[1,5-.alpha.][1,4]diazepine derivatives as ros1 inhibitors Download PDFInfo
- Publication number
- CA2940918C CA2940918C CA2940918A CA2940918A CA2940918C CA 2940918 C CA2940918 C CA 2940918C CA 2940918 A CA2940918 A CA 2940918A CA 2940918 A CA2940918 A CA 2940918A CA 2940918 C CA2940918 C CA 2940918C
- Authority
- CA
- Canada
- Prior art keywords
- substituted
- 6alkyl
- hydrogen
- formula
- cyano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14161950.2 | 2014-03-27 | ||
| EP14161950 | 2014-03-27 | ||
| PCT/EP2015/056498 WO2015144799A1 (en) | 2014-03-27 | 2015-03-26 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRAZINE DERIVATIVES AND 5,6,7,8-TETRAHYDRO-4H-PYRAZOLO[1,5-a][1,4]DIAZEPINE DERIVATIVES AS ROS1 INHIBITORS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2940918A1 CA2940918A1 (en) | 2015-10-01 |
| CA2940918C true CA2940918C (en) | 2023-10-24 |
Family
ID=50389872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2940918A Active CA2940918C (en) | 2014-03-27 | 2015-03-26 | Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-.alpha.]pyrazine derivatives and 5,6,7,8-tetrahydro-4h-pyrazolo[1,5-.alpha.][1,4]diazepine derivatives as ros1 inhibitors |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10280170B2 (https=) |
| EP (1) | EP3129376B1 (https=) |
| JP (1) | JP6522646B2 (https=) |
| KR (1) | KR102455519B1 (https=) |
| CN (1) | CN106164076B (https=) |
| AU (1) | AU2015238296B2 (https=) |
| BR (1) | BR112016022105B1 (https=) |
| CA (1) | CA2940918C (https=) |
| EA (1) | EA032255B1 (https=) |
| ES (1) | ES2715676T3 (https=) |
| IL (1) | IL247947B (https=) |
| MX (1) | MX367914B (https=) |
| WO (1) | WO2015144799A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102630720B1 (ko) | 2015-08-28 | 2024-01-29 | 세키스이 메디칼 가부시키가이샤 | 벤질 화합물 |
| TWI782056B (zh) * | 2017-07-14 | 2022-11-01 | 日商鹽野義製藥股份有限公司 | 具有ｍｇａｔ２抑制活性的縮合環衍生物 |
| WO2019233456A1 (zh) * | 2018-06-08 | 2019-12-12 | 贝达药业股份有限公司 | Erk抑制剂及其应用 |
| CA3126334A1 (en) * | 2019-01-11 | 2020-07-16 | Shionogi & Co., Ltd. | Dihydropyrazolopyrazinone derivative having mgat2 inhibitory activity |
| JP7068743B2 (ja) * | 2019-01-11 | 2022-05-17 | 塩野義製薬株式会社 | Ｍｇａｔ２阻害活性を有する縮合環誘導体を含有する医薬組成物 |
| US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN114315866B (zh) * | 2020-09-30 | 2023-10-31 | 烟台药物研究所 | 一种盐酸左旋咪唑的合成方法 |
| TW202229282A (zh) * | 2020-09-30 | 2022-08-01 | 美商史考皮恩治療有限公司 | 治療癌症之方法 |
| WO2022127756A1 (en) * | 2020-12-15 | 2022-06-23 | Gritscience Biopharmaceuticals Co., Ltd. | Compounds as casein kinase inhibitors |
| CN114957259A (zh) * | 2021-02-25 | 2022-08-30 | 南京明德新药研发有限公司 | 氰基取代的芳香双环类化合物及其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5356897A (en) | 1991-09-09 | 1994-10-18 | Fujisawa Pharmaceutical Co., Ltd. | 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines |
| EP1505068A4 (en) | 2002-04-23 | 2008-03-19 | Shionogi & Co | PYRAZOLO (1,5-a) PYRIMIDINE DERIVATIVE AND INHIBITOR OF NAD (P) H OXIDASE CONTAINING SAID DERIVATIVE |
| KR101050700B1 (ko) | 2002-08-26 | 2011-07-20 | 다케다 야쿠힌 고교 가부시키가이샤 | 칼슘 수용체 조절 화합물 및 이의 용도 |
| CN1747949A (zh) * | 2002-12-20 | 2006-03-15 | 法马西亚公司 | 无环吡唑化合物 |
| JP2005343889A (ja) * | 2004-05-06 | 2005-12-15 | Taisho Pharmaceut Co Ltd | イミダゾピリジン誘導体 |
| US8288375B2 (en) * | 2007-12-12 | 2012-10-16 | E.I. Du Pont De Nemours And Company | Fungicidal bicyclic pyrazoles |
| CN101952293A (zh) | 2007-12-21 | 2011-01-19 | 惠氏有限责任公司 | 吡唑并[1,5-a]嘧啶化合物 |
| US20100029657A1 (en) * | 2008-02-29 | 2010-02-04 | Wyeth | Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof |
| US8592432B2 (en) | 2008-04-07 | 2013-11-26 | Bei Chen | Compounds and compositions as protein kinase inhibitors |
| KR20110002080A (ko) * | 2008-04-07 | 2011-01-06 | 아이알엠 엘엘씨 | 키나제 억제제로서의 화합물 및 조성물 |
| WO2009140128A2 (en) * | 2008-05-13 | 2009-11-19 | Irm Llc | Compounds and compositions as kinase inhibitors |
| CN102459264A (zh) * | 2009-05-27 | 2012-05-16 | 雅培制药有限公司 | 激酶活性的嘧啶抑制剂 |
| AU2010254151B2 (en) | 2009-05-28 | 2013-11-28 | Cook Medical Technologies Llc | Tacking device and methods of deployment |
| WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| AU2012291744A1 (en) * | 2011-08-02 | 2014-02-20 | Pfizer Inc. | Crizotinib for use in the treatment of cancer |
| TWI585088B (zh) * | 2012-06-04 | 2017-06-01 | 第一三共股份有限公司 | 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物 |
-
2015
- 2015-03-26 EP EP15713436.2A patent/EP3129376B1/en active Active
- 2015-03-26 CN CN201580016470.XA patent/CN106164076B/zh active Active
- 2015-03-26 JP JP2016559326A patent/JP6522646B2/ja active Active
- 2015-03-26 AU AU2015238296A patent/AU2015238296B2/en active Active
- 2015-03-26 US US15/129,582 patent/US10280170B2/en active Active
- 2015-03-26 ES ES15713436T patent/ES2715676T3/es active Active
- 2015-03-26 WO PCT/EP2015/056498 patent/WO2015144799A1/en not_active Ceased
- 2015-03-26 EA EA201691930A patent/EA032255B1/ru not_active IP Right Cessation
- 2015-03-26 BR BR112016022105-2A patent/BR112016022105B1/pt active IP Right Grant
- 2015-03-26 MX MX2016012668A patent/MX367914B/es active IP Right Grant
- 2015-03-26 CA CA2940918A patent/CA2940918C/en active Active
- 2015-03-26 KR KR1020167028572A patent/KR102455519B1/ko active Active
-
2016
- 2016-09-21 IL IL247947A patent/IL247947B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015238296A1 (en) | 2016-09-08 |
| EA032255B1 (ru) | 2019-04-30 |
| CN106164076B (zh) | 2019-03-26 |
| BR112016022105B1 (pt) | 2023-01-31 |
| EP3129376A1 (en) | 2017-02-15 |
| IL247947B (en) | 2019-03-31 |
| EA201691930A1 (ru) | 2017-02-28 |
| BR112016022105A2 (https=) | 2017-08-15 |
| CA2940918A1 (en) | 2015-10-01 |
| ES2715676T3 (es) | 2019-06-05 |
| CN106164076A (zh) | 2016-11-23 |
| AU2015238296B2 (en) | 2018-10-18 |
| MX367914B (es) | 2019-09-11 |
| EP3129376B1 (en) | 2018-12-26 |
| KR20160137576A (ko) | 2016-11-30 |
| JP6522646B2 (ja) | 2019-05-29 |
| MX2016012668A (es) | 2016-12-14 |
| US20170174690A1 (en) | 2017-06-22 |
| WO2015144799A1 (en) | 2015-10-01 |
| US10280170B2 (en) | 2019-05-07 |
| KR102455519B1 (ko) | 2022-10-14 |
| JP2017508779A (ja) | 2017-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2940918C (en) | Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-.alpha.]pyrazine derivatives and 5,6,7,8-tetrahydro-4h-pyrazolo[1,5-.alpha.][1,4]diazepine derivatives as ros1 inhibitors | |
| EP3967695B1 (en) | 1-(7-(quinazolin-4-yl)-2,7-diazaspiro[3.5]nonan-2-yl)prop-2-en-1-one derivatives as kras inhibitors for the treatment of cancer | |
| AU2021202973B2 (en) | Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity | |
| JP6925435B2 (ja) | ピリミジニル−ピリジルオキシ−ナフチル化合物及びｉｒｅ１関連疾患及び障害を治療する方法 | |
| US20230265116A1 (en) | Degradation of (egfr) by conjugation of egfr inhibitors with e3 ligase ligand and methods of use | |
| TW202134229A (zh) | 環烷基尿素衍生物 | |
| AU2015238298B2 (en) | Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrimidine derivatives and 2,3-dihydro-1H-imidazo[1,2-b]pyrazole derivatives as ROS1 inhibitors | |
| JP2017508779A5 (https=) | ||
| AU2021227907A1 (en) | Potent and selective degraders of ALK | |
| CA3011880A1 (en) | Substituted cyanoindoline derivatives as nik inhibitors | |
| JP2017508777A5 (https=) | ||
| JP7281834B2 (ja) | Ｐｄ－ｌ１拮抗薬化合物 | |
| TW202428279A (zh) | 一種ｋｒａｓ ｇ１２ｄ抑制劑及其應用 | |
| EP4393924A1 (en) | Imidazo [1,2-a] pyrazine or pyrazolo [1,5-a] pyrimidine derivative and use thereof | |
| CN110078743A (zh) | 用作激酶活性调节剂的新颖的咪唑-哌啶基衍生物 | |
| EP4495111A1 (en) | Novel compound and use thereof for inhibiting checkpoint kinase 2 | |
| WO2025117881A1 (en) | Compounds and methods for inhibiting autophagy | |
| CA3260373A1 (en) | MACROCYCLICAL BCL6 DEGRADING AGENTS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200312 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD Year of fee payment: 10 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241223 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241223 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241223 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD Year of fee payment: 11 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260203 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260203 |